What's behind Reckitt Benckiser's latest 1.6% stock pullback?

Traders Union
All News
Stocks
Reckitt benckiser drops 1.56% today

Highlights

UBS projects that persistent early flu levels could raise Reckitt Benckiser's 2027 like-for-like sales growth to 5.2%.
UBS estimates 2027 adjusted earnings per share could be 4% above consensus, with the stock at 14.9 times projected earnings.
Reckitt Benckiser stock trades with strong bullish momentum and is forecast between GBX5,343 and GBX5,521 over the next five sessions, but several oscillators indicate overbought conditions.

Earnings forecast revise potential as flu trends counter selling

UBS indicated that an early rise in flu incidence could positively affect Reckitt Benckiser's 2027 earnings forecasts. UBS analysis suggested the company's like-for-like sales growth could reach 5.2% in 2027 if current flu levels persist, with adjusted earnings per share potentially 4% above consensus. The company was also referenced as trading at 14.9 times forecast 2027 earnings, though price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, notes that Reckitt Benckiser's technical signals remain strong, yet this masks deeper concerns. He sees persistent selling pressure weighing on price action despite bullish momentum and support above major moving averages. Kharitonov points out the overextension in multiple oscillators and warns that volatility remains elevated after a downside gap. He is cautious about the reliability of optimistic forecasts, with long-term technical alignment still indicating a bearish trend. "Short-term momentum can be deceptive when broader trend and sentiment headwinds persist — risk of a pullback remains high for Reckitt Benckiser."

Viktoras Karapetjanc, expert at Traders Union, views Reckitt Benckiser’s outlook as promising. He highlights positive UBS news, with rising flu incidence supporting upgraded earnings and sales projections for 2027. The analyst sees the bullish price structure intact above all key averages, and expects further growth if near-term resistance breaks. Karapetjanc emphasizes that strong momentum and upbeat forecasts offer opportunities ahead. "Current setup favors buyers, and I expect Reckitt Benckiser to benefit from robust fundamentals and healthy macro tailwinds."

Sholanke Dele, market strategist, sees increased volatility and possible weakness under current conditions. He notes that despite bullish indicators, the gap down suggests sellers are still influential. Dele warns that overbought signals on several technical gauges increase the risk of a near-term correction. "I remain wary of prolonged upside when intraday action shows clear selling pressure and technicals look stretched."

Bullish momentum persists while oscillators flash overbought risk

Reckitt Benckiser trades above its 20-day (GBX5,128), 50-day (GBX5,106), and 200-day (GBX5,250) moving averages, signaling firm bullish momentum across all timeframes. Immediate range is set by a near-term ceiling at GBX5,444 and a near-term floor at GBX5,392, with the Ichimoku Kijun at GBX5,210 providing structural support beneath the price, although the longer-term trend remains bearish by MA-50 vs MA-200 alignment. Momentum readings remain strong, with both Moving Average Convergence Divergence (MACD) and Average Directional Index (ADX) signaling robust buying. The Relative Strength Index (RSI) and Commodity Channel Index (CCI) identify overbought territory, echoed by Stochastic RSI and Bull/Bear Power (BBP), which shows buyers dominating intraday action but also flag a potential overextension. The Awesome Oscillator (AO) confirms upside momentum. The stock is trading at GBX5,432, down 86 points or 1.56% after opening with a downside gap of around 0.87%. The price sits near the day’s low, daily volatility is 1.03%, and there is clear pressure after the open. Momentum signals confirm ongoing strength, but multiple oscillators warn of stretched conditions.

Previously it was reported that Reckitt Benckiser was weighing strategic options for its nutrition business amid rising sector litigation and uncertainty. The current technical view shifts focus to the consumer health segment and highlights immediate risk management considerations, with GBX5,444 as a key resistance level and GBX5,392 as essential near-term support for active positioning.

Source of Data: RKT Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.